Article Type
Changed
Tue, 05/03/2022 - 16:11
Display Headline
Ramipril lowered cardiovascular risk, but vitamin E did not
The HOPE study
Article PDF
Author and Disclosure Information

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Issue
Cleveland Clinic Journal of Medicine - 67(4)
Publications
Topics
Page Number
287-293
Sections
Author and Disclosure Information

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Author and Disclosure Information

Byron J. Hoogwerf, MD
Department of Endocrinology, Director, Internal Medicine Residency Program, Cleveland Clinic; investigator, Heart Outcomes Prevention Evaluation (HOPE) study

James B. Young, MD
Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic; member, steering committee, Heart Outcomes Prevention Evaluation (HOPE) study

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; hoogweb@ccf.org

This paper discusses off-label uses of medication. The HOPE study was funded by the Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King Pharmacuticals, Natural Source Vitamin E Association, Negma, and the Heart and Stroke Foundation of Ontario.

Drs. Hoogwerf and Young serve as consultants for Monarch Pharmaceuticals.

Article PDF
Article PDF
Related Articles
The HOPE study
The HOPE study
Issue
Cleveland Clinic Journal of Medicine - 67(4)
Issue
Cleveland Clinic Journal of Medicine - 67(4)
Page Number
287-293
Page Number
287-293
Publications
Publications
Topics
Article Type
Display Headline
Ramipril lowered cardiovascular risk, but vitamin E did not
Display Headline
Ramipril lowered cardiovascular risk, but vitamin E did not
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media